ARCA biopharma Announces FDA Acceptance Of Gencaro IND Application For The Treatment Of Atrial Fibrillation
Published: Dec 04, 2013
WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the Company’s GencaroTM Investigational New Drug (IND) application for atrial fibrillation (AF) has been accepted by the U.S. Food and Drug Administration (FDA) and is now active.
Help employers find you! Check out all the jobs and post your resume.